Friday October 20th 2017

Teva marketing strategies investigated by U.S. Attorney’s Office

Teva Pharmaceuticals Ltd. disclosed Monday it recently received a civil investigative demand from the U.S. Attorney’s Office in New York City seeking documents and information related to the company’s sales, marketing and promotion of two products: Copaxone and Azilect. Copaxone is used to treat multiple sclerosis. Azilect is medicine for patients suffering from Parkinson’s disease. The U.S. Attorney’s Office is seeking information on the sales practices for the two drugs from Jan. 1, 2006… (Source: bizjournals.com Health Care:Biotechnology headlines)

Continued here:

Teva marketing strategies investigated by U.S. Attorney’s Office

Leave a Comment

More from category

OHSU’s Robertson on coming to grips with his diagnosis
OHSU’s Robertson on coming to grips with his diagnosis

After learning that he has multiple sclerosis, Dr. Joe Robertson was in denial. Then he realized there was no other [Read More]

Concussion in teens increase risk of multiple sclerosis
Concussion in teens increase risk of multiple sclerosis

Researchers from Orebro University in Sweden studied the connection between concussions and multiple sclerosis. They [Read More]

Phys Ed: Concussions in Teenagers Tied to Multiple Sclerosis Risk
Phys Ed: Concussions in Teenagers Tied to Multiple Sclerosis Risk

A large-scale new study found that concussions in adolescents can increase the risk of later developing multiple [Read More]

Multiple sclerosis: Oligodendrocytes from stemmcells
Multiple sclerosis: Oligodendrocytes from stemmcells

(Heinrich-Heine University Duesseldorf) A scientific collaboration between stem cell researchers of the [Read More]

Global Experts Publish Recommendations for Overcoming Challenges to Improve Clinical Trials in Progr
Global Experts Publish Recommendations for Overcoming Challenges to Improve Clinical Trials in Progr

/About-the-Society/News/Global-Experts-Publish-Recommendations-for-Overcom [Read More]